ContractUnited States-Mexico-Canada Agreement (Usmca) • June 19th, 2019
Contract Type FiledJune 19th, 2019On November 30, 2018, President Trump signed the renegotiated NAFTA trade deal and put Congress on notice that it will send lawmakers a bill to implement the United States- Mexico-Canada (UMSCA) Agreement, also known as NAFTA 2.0. Congress must vote to approve the agreement for it to be finalized; a NAFTA 2.0 vote is likely to happen in 2019. The trade agreement contains provisions that could affect drug prices for all Americans, including seniors, by locking out generic competition for long periods and locking in new patents on old drugs when minor tweaks are made (such as a new shape or higher dosage). It would also jeopardize the U.S. government’s ability to lower drug prices for taxpayers and patients in the future.
ContractUnited States-Mexico-Canada Agreement (Usmca) • February 5th, 2019
Contract Type FiledFebruary 5th, 2019On November 30, 2018, President Trump signed the renegotiated NAFTA trade deal and put Congress on notice that it will send lawmakers a bill to implement the United States- Mexico-Canada (UMSCA) Agreement, also known as NAFTA 2.0. Congress must vote to approve the agreement for it to be finalized; a NAFTA 2.0 vote is likely to happen in 2019. The trade agreement contains provisions that could affect drug prices for all Americans, including seniors, by locking out generic competition for long periods and locking in new patents on old drugs when minor tweaks are made (such as a new shape or higher dosage). It would also jeopardize the U.S. government’s ability to lower drug prices for taxpayers and patients in the future.